IL-2 production by intestinal lamina propria cells in normal inflamed and cancer-bearing colons
Open Access
- 1 April 1992
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 88 (1) , 132-137
- https://doi.org/10.1111/j.1365-2249.1992.tb03052.x
Abstract
Biologically significant levels of IL-2 activity were produced by isolated lamina propria mononuclcar cells (LPMC) from normal intestine (n= 12). cancer-bearing colons (n= 35) and inflammatory bowel disease (IBD) affected tissue (n= 12). The levels of IL-2 produced were similar for all three sources of LPMC (normal 252 ± 48 U/ml, I BD-affected mucosa 197 ± 42 U/ml and colon cancer 285 ± 43 U/ml). These levels were significantly greater than those produced by peripheral blood mononuclcar cells (20·5 U/ml, P < 0·01) on a per cell basis. In mucosa from cancer-bearing colons the amount of IL-2 produced by LPMC was unaffected by the invasiveness of the colon cancer. LPMC IL-2 production was markedly suppressed by drugs used in IBD therapy. 5-Aminosalicylic acid (5-ASA) reduced activity in a dose-dependent fashion. At a dose equivalent to the faecal therapeutic level of 0·5 mg/ml activity, IL-2 production by LPMC was suppressed to 3·4% of controls. Similarly, exposure of LPMC to cyclosporin A (CyA) and hydrocortisone (HC) at therapeutic levels reduced I L-2 activity to less than 1% of controls. The major producers of IL-2 activity were shown to be CD3+ T lymphocytes and those bearing the activation markers IL-2R and TFR. Suppression of mucosal IL-2 production represents an important therapeutic mechanism ofdrugs used in the management of IBD including HC, 5-ASA and CyA. These results suggest that mucosal T cells produce appreciable levels of IL-2 activity that may be important in maintaining immune homeostasis in the normal intestine, provide anti-neoplastic cytotoxic activity and contribute to the inflammatory events that characterize the mucosal lesions of IBD.Keywords
This publication has 41 references indexed in Scilit:
- Plasma and tissue interleukin-2 receptor levels in inflammatory bowel diseaseClinical and Experimental Immunology, 1990
- Soluble interleukin-2 receptor in Crohn's disease: relation of serum concentrations to disease activity.Gut, 1990
- Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. Effect of cyclosporin.Gut, 1990
- Immunosuppressive Drugs in Inflammatory Bowel DiseaseDrugs, 1989
- Pharmacology and pharmacokinetics of 5-aminosalicylic acidDigestive Diseases and Sciences, 1987
- Possible mode of action of 5-aminosalicylic acidDigestive Diseases and Sciences, 1987
- BLOCKING OF DELIVERY OF THE ANTIGEN-MEDIATED SIGNAL TO THE NUCLEUS OF T CELLS BY CYCLOSPORINSTransplantation, 1987
- Does cyclosporine act in vivo as it does in vitro?Immunology Today, 1986
- Lymphokine and nonlymphokine mRNA levels in stimulated human T cells. Kinetics, mitogen requirements, and effects of cyclosporin A.The Journal of Experimental Medicine, 1986
- Interleukin 2: the molecule and its functionImmunology Today, 1984